The Board of Oslo Cancer Cluster is made up of nine highly skilled and experienced member representatives whom reflect the oncology value chain from research to pharmaceutical industry.
Henrik Lund has been a board member since 2008. Lund is an MD PhD from University of Oslo and received his post-doctoral training at UC San Francisco in lipidology.
In 2005 – 2010 Lund served as VP of AstraZenecas Marketing Company clinical development group. He has also served as CEO and Chairman of the Board of several Norwegian biotech/life science companies.
Lund is now CEO of Regenics AS, a partner of Life Capitol AS and Chairman of the Board of Arctic Nutrition AS.
Ludvik Sandnes has more than 40 years of experience from international corporate finance, banking and asset management.
He is Chairman of the Board of Nordic Nanovector ASA, listed on the Oslo Stock Exchange, and board member of Oncoinvent AS, Oslo Cancer Cluster, Godthaab Helse og Rehabilitering and Pioner Fonds AS.
Ludvik holds degrees as Siviløkonom and Certified European Financial Analyst (AFA) from the Norwegian School of Economics and Business Administration.
Sandnes became a member of the Oslo Cancer Cluster board in 2015.
Benedikte Thunes Akre
Benedikte Thunes Akre has a Cand. Pharm degree from the University of Oslo as well as Bachelor Degree in Biomedical Sciences. She has a long line of experience working within the pharmaceutical industry including preclinical pharmacology, regulatory, safety, marketing and medical affairs.
Thunes Akre has worked for Bristol-Myers Squibb the last 18 years and was until recently part of the Global Medical Affairs organization within Immuno-Oncology. She is currently working in Astra Zeneca as Medical Director, Nordics & Baltics.
Unni Hjelmaas is CEO of Bionor Pharma and joined the board of Oslo Cancer Cluster in May 2014.
Hjelmaas has extensive senior management experience from Roche, and is former CEO of Lytix Biopharma. Hjelmaas has substantial experience from oncology, life cycle management, international strategy and marketing experience from Roche HQ in Basel.
Unnni Hjelmaas is also former Chairman of the Board of the Norwegian Pharma Industry Association. She has a Cand.pharm degree in Pharmacy from the University of Oslo.
Inger Sandlie is professor at the Department of Biosciences, University of Oslo and research group leader at the Department of Immunology, Oslo University Hospital. She is also deputy director of the Centre for Immune Regulation.
Sandlie has co-authored more than 120 publications, supervised 15 PhDs, received awards for scientific innovation and is co-founder of Nextera A/S and Vaccibody A/S.
She presently consults for Syntimmune A/S (Boston, US) as well as Albumedix A/S (Nottingham, UK), and serves on the board of the technology transfer office of the University of Oslo (Inven2) and The Norwegian Radium Hospital Research Foundation.
Bjørn Tore Gjertsen
Bjørn Tore Gjertsen jr. is Professor at Department of Clinical Science at the University of Bergen, and Clinical Chief at the early phase Clinical Trials Unit at Haukeland University Hospital – Helse Bergen. He joined the board of Oslo Cancer Cluster in May 2014.
Gjertsen is consultant hematologist with special focus on acute and chronic myeloid leukemia. He participates as project leader and principle investigator in the Centre of Excellence in Cancer Biomarkers CCBIO and the medical visualization cluster MedViz, University of Bergen and Helse Bergen, with special interest in early phase clinical trials with integrated fuctonal screens and accompanied diagnostics.
Gjertsen is also board member in two small biotech companies developing new cancer therapy.
Kirsten Haugland is Head of the Research and Prevention Department at the Norwegian Cancer Society. She joined the Board of Oslo Cancer Cluster in May 2015.
Kirsten Haugland has been working in Norwegian Cancer Society since 2010. She has 25 years’ experience from hospitals and more than 15 in leadership positions. During many years in cancer care for children and their families, Haugland focused on organizational development and patient involvement. Ms. Haugland is also responsible for and engaged in different leadership development programs. Ms. Haugland holds a Master of Health Economics and Health Management from the University of Oslo and a Bachelor in Nursing with specialization in cancer care.
Ms. Haugland has participated to several leadership programs, among others an executive management program in strategy and innovation at INSEAD in 2014.
Øyvind Bruland is professor of clinical oncology at the University of Oslo and consultant oncologist at Radiumhospitalet - Oslo University Hospital.
Bruland specializes in primary bone and soft tissue cancers as well as skeletal metastases brought on by prostate and breast cancer. He has contributed to numerous publications dedicated to cancer research.
Bruland is one of the founders of the successful Norwegian biotech companies Algeta and Nordic Nanovector.
Ole Dahlberg has more than 15 years’ international life science management experience. He joined the board of Oslo Cancer Cluster in June 2016.
Dahlberg is Managing Director for Thermo Fisher Norway and in the leadership group of License- and Commercial Supply in Thermo Fisher Scientic.
Kaare R. Norum
Kaare R. Norum is Professor Emeritus at the University of Oslo and Honourable Member of the Oslo Cancer Cluster and the Board of the Oslo Cancer Cluster. Norum is the initiator of both the Oslo Cancer Cluster and the Oslo Cancer Cluster Innovation Park, together with Jónas Einarsson, CEO of the Radium Hospital Research Foundation.
Norum was Professor in Medicine and Nutrition from 1972 until 2002 at Institute for Nutrition Research, University of Oslo. He has chaired the National Nutrition Council of Norway for several years. He was associate Dean and then later, Dean for the Medical Faculty, University of Oslo. He also served as principal of the University of Oslo for some years.
Norum was member of the UN Commission of the Nutrition Challenges of the 21st Century and member of the Board for the WHO Multicentre Growth Reference Study. He has served as the Chair for the Reference Group of WHO project on the "Global Strategy for Diet, Physical Activity and Health” 2002-2004, and he was Chair of an Expert Group on “Counteracting Obesity in Europe” serving the European Regional Office of WHO.
He is Commander of The Royal Norwegian Order of St. Olav, and Commander of the Royal Swedish Order of the Northern Star.
Jónas Einarsson, M.D., is the CEO of the Radium Hospital Research Foundation. He is also on the Management Team of the Oslo Cancer Cluster Innovation Park. Einarsson is the founder and former CEO and Chairman of the board of Oslo Cancer Cluster and the Oslo Cancer Cluster Innovation Park.
The Radium Hospital Research Foundation is an experienced pre-seed investor and project developer focused on cancer. Their focus is on startup companies based on Norwegian research within immunoncology. During his time as CEO, Einarsson has been involved in more than 20 startups.
Einarsson was the CEO and Chairman of the board of Norway’s first private hospital, Oslo Private Sykehus AS. He acted as General Practitioner and Chief Medical Officer of Lardal Municipality for ten years.